H.C. Wainwright Keeps a Buy Rating on Trevena (TRVN)


In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Trevena (TRVN), with a price target of $5.00. The company’s shares closed last Monday at $2.69.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 10.9% and a 50.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevena with a $5.25 average price target.

See today’s analyst top recommended stocks >>

Based on Trevena’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.22 million. In comparison, last year the company had a GAAP net loss of $4.69 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts